ELCC 2025 Satellite Symposium: Professor Francesco Grossi
Recorded at a promotional symposium organised and funded by Accord Healthcare Ltd as part of ELCC 2025. Watch Professor Francesco Grossi (Director of Division of Medical Oncology – Department of Medicine and Technological Innovation, Italy) talk through HETRONIFLY®(serplumimab) mechanism of action and the associated receptors.
This video has been taken from Professor Grossi’s full-length symposium Emerging chemo-immunotherapy data in first-line treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC).
Do you have any questions or are you looking to Request a Meeting with a local Accord Representative? Click the button above to get in touch.
Duration : 01:35 min
Professor Francesco Grossi
Professor Francesco Grossi is currently Director of the Division of Medical Oncology at IRCCS Policlinico San Martino in Genova, Italy.
His main areas of interest include lung cancer, mesothelioma, translational research in thoracic oncology, and new drug development. He serves as principal investigator and coordinator for several international and national clinical trials, and as project leader for multiple translational research initiatives.
He earned his medical degree from the University of Genova, where he also completed his internship and residency in biochemistry and oncology.
Prior to his current role, he served as Deputy Head of the Division of Clinical Oncology at the University of Udine (1999–2003); Director of the Lung Cancer Unit, Lung Cancer Translational Research Laboratory, and Chairman of the Lung Cancer Disease Management Team at the National Institute for Cancer Research in Genova (2003–2018); and later as Director of the Division of Medical Oncology at the Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico in Milan (2018–2021).
From 2021 to 2025, he was Full Professor of Medical Oncology at the University of Insubria and Director of the Division of Medical Oncology at ASST dei Sette Laghi in Varese.
He is an active member of several international scientific societies, including ASCO, ESMO, and IASLC.
Professor Grossi has authored more than 270 articles indexed in PubMed and has been invited to lecture at numerous national and international conferences.
HETRONIFLY® in combination with carboplatin and etoposide is indicated for the first-line treatment of adult patients with extensive-stage small-cell lung cancer (ES-SCLC).1
ASCO, American Society of Clinical Oncology; ELCC, European Lung Cancer Congress; ESMO, European Society for Medical Oncology; IASLC, International Assoication for the Study of Lung Cancer; IRCCS, Istituto di Ricovero e Cura a Carattere Scientifico.
References:
- HETRONIFLY® Summary of Product Characteristics
Related Content
